Neutropenia due to Tacrolimus in a Cadaveric Renal Transplant Patient

Yelda Deligöz Bildacı, Ömer Celal Elçioğlu, Yunus Taşçı, Meltem Gürsu and Rümeyza Kazancıoğlu

Department of Nephrology, Bezmialem University, Turkey
Bezmialem University, General Surgery Department, Turkey

^*Correspondance to: Rümeyza Kazancıoğlu 

 PDF  Full Text Case Report | Open Access

Abstract:

Myelosuppression is known to occur in kidney transplant recipients because of widely used immunosuppressant chemotherapeutic agents. Myelosuppression usually results with leukopenia and less often with neutropenia representing with percentages of 10 to 55% and 4.9 to 37.5% respectively [1,2]. Bone marrow toxicity caused by medications, systemic infections or posttransplant lymphoproliferative disease are the possible etiology of neutropenia. Also neutropenia can both be the result of decreased neutrophil production from inefficient granulopoesis because of afore-mentioned reasons or increased peripheral destruction. Tacrolimus, which is one of the most important part of kidney transplantation immunosuppressive protocols, has a very rare effect of myelosuppression other than metabolic side effects which are more common. In this case report we aimed to describe a patient with severe neutropenia developed six months after a cadaveric renal transplantation.

Keywords:

Cite the Article:

Bildacı YD, Elçioğlu ÖC, Taşçı Y, Gürsu M, Kazancıoğlu R. Neutropenia due to Tacrolimus in a Cadaveric Renal Transplant Patient. Ann Clin Case Rep. 2016; 1: 1203.